Ionis Pharmaceuticals Inc (IONS) Chairman Sells $572,110.00 in Stock

Ionis Pharmaceuticals Inc (NASDAQ:IONS) Chairman Stanley T. Crooke sold 11,000 shares of the stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $52.01, for a total value of $572,110.00. Following the transaction, the chairman now directly owns 48,014 shares of the company’s stock, valued at $2,497,208.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) opened at $53.17 on Friday. Ionis Pharmaceuticals Inc has a 52-week low of $37.26 and a 52-week high of $65.51. The stock has a market capitalization of $6,610.00, a P/E ratio of 379.79 and a beta of 2.86. The company has a debt-to-equity ratio of 1.50, a current ratio of 6.25 and a quick ratio of 6.21.

Several institutional investors and hedge funds have recently added to or reduced their stakes in IONS. Steward Partners Investment Advisory LLC acquired a new stake in shares of Ionis Pharmaceuticals in the third quarter valued at approximately $100,000. Hanseatic Management Services Inc. lifted its position in shares of Ionis Pharmaceuticals by 1.2% in the second quarter. Hanseatic Management Services Inc. now owns 3,481 shares of the company’s stock valued at $177,000 after buying an additional 41 shares during the last quarter. Parallel Advisors LLC lifted its position in shares of Ionis Pharmaceuticals by 60.3% in the third quarter. Parallel Advisors LLC now owns 3,323 shares of the company’s stock valued at $182,000 after buying an additional 1,250 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Ionis Pharmaceuticals by 9.1% in the second quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock valued at $190,000 after buying an additional 311 shares during the last quarter. Finally, WFG Advisors LP lifted its position in shares of Ionis Pharmaceuticals by 77.2% in the second quarter. WFG Advisors LP now owns 3,800 shares of the company’s stock valued at $193,000 after buying an additional 1,655 shares during the last quarter. 91.40% of the stock is owned by institutional investors.

Several brokerages recently commented on IONS. Needham & Company LLC reissued a “buy” rating and set a $64.00 price target on shares of Ionis Pharmaceuticals in a research report on Tuesday, October 17th. BMO Capital Markets reissued an “outperform” rating and set a $69.00 price target on shares of Ionis Pharmaceuticals in a research report on Monday, October 2nd. Barclays reduced their price target on Ionis Pharmaceuticals from $55.00 to $52.00 and set an “equal weight” rating for the company in a research report on Thursday, September 21st. BidaskClub cut Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, December 22nd. Finally, Zacks Investment Research cut Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $50.76.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/01/12/ionis-pharmaceuticals-inc-ions-chairman-sells-572110-00-in-stock.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

What are top analysts saying about Ionis Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ionis Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit